- Home
- TCRX vs ANL Comparison
TCRX vs ANL Comparison
Compare TCRX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCRX | ANL |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 62.0M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TCRX | ANL |
|---|---|---|
| Price | $1.19 | $1.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 554.3K | ★ 1.3M |
| Earning Date | 03-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,423,000.00 | N/A |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.88 |
| 52 Week High | $2.67 | $2.75 |
Technical Indicators
Market Signals| Indicator | TCRX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 67.92 |
| Support Level | $1.09 | $1.63 |
| Resistance Level | $1.27 | $1.93 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 70.81 | 89.36 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.